Revolutionizing Cancer Therapy with Conditionally Active Biologics

Play Video

Conditionally Active Biologics (CAB)

BioAtla®’s revolutionary patented platform for developing conditionally active therapeutics yields antibodies (as well as other biologics) that can be activated or inactivated under defined physiological conditions.

CAB technology takes advantage of the unique microenvironment associated with different diseases and tissues, which can result for example from differences in metabolism between diseased and normal tissue. For example, in cancer the unique cell metabolism described by Warburg contributes to a characteristic microenvironment that activates our antibodies when they are in close proximity to a tumor, and reversibly inactivates our antibodies if they drift away from the tumor.

  • The unique physiology and metabolism of a diseased tissue is used to locally activate a biologic, even if its target is also found in normal tissue
  • Activation of the biologic is reversible, such that it can be inactivated and reactivated as it passes from diseased to normal to diseased tissue
  • No exogenous (for example non-antibody) sequence is introduced
  • Can be applied to antibody therapeutics including naked antibodies and ADC’s, cell therapies such as CAR-T, enzyme therapies, or other biologics
BioAtla® is developing CAB versions of immune checkpoint antibodies to enable combination therapy without the toxicity.
CAB technology enables more safe and potent ADC’s, as well as cancer targets also found in normal tissue.
CAB technology can improve the safety and potency of CAR-T therapy, in particular for solid tumors.